CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing prevalence of chronic diseases
4.1.2. Growing funding for development of efficient live cell imaging techniques
4.1.3. Increasing usage of high content screening techniques in drug discovery
4.1.4. Government funding for cell-based research
4.1.5. Wide area applications of live cell imaging
4.2.Market Restraints & Challenges
4.2.1. Expensive cost of high content screening systems
4.2.2. Lack of skilled professionals
4.2.3. Maintaining cell viability & cellular environment in the culture
4.3.Market Opportunities
4.3.1. Adoption of HCS for primary screening& emerging economies
4.3.2. Applications of live cell imaging techniques in personalised medicine
CHAPTER 5. GLOBAL LIVE CELL IMAGING MARKET– BY PRODUCT
5.1. Instruments
5.1.1. Standalone Systems
5.1.2. Microscopes
5.1.2.1.Conventional Microscopes
5.1.2.2. Confocal Microscopes
5.1.2.3. Advanced Fluorescence Microscopes
5.1.3. Cell Analyzers
5.1.5. Image Capturing Devices
5.2. Consumables
5.2.1. Assay Kits
5.2.2. Reagents
5.2.3. Media
5.2.4. Others
5.3. Software
CHAPTER 6. GLOBAL LIVE CELL IMAGING MARKET – BY TECHNOLOGY
6.1. Fluorescence Resonance Energy Transfer
6.2. High-Content Screening
6.3. Fluorescence Recovery after Photobleaching
6.4. Fluorescence in Situ Hybridization
6.5. Ratiometric Imaging
6.6. Total Internal Reflection Fluorescence Microscopy
6.7. Multiphoton Excitation Microscopy
6.8. Others
CHAPTER 7. GLOBAL LIVE CELL IMAGING MARKET – BY APPLICATION
7.1. Cell Biology
7.2. Stem Cells
7.3. Developmental Biology
7.4. Drug Discovery
CHAPTER 8. GLOBAL LIVE CELL IMAGING MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL LIVE CELL IMAGING MARKET - COMPANY PROFILES
9.1. Nikon Corporation
9.2. Beckton, Dickinson and Company
9.3. GE Healthcare
9.4. Olympus Corporation
9.5. Thermo Fisher Scientific
9.6. Sigma-Aldrich Corporation
9.7. Carl Zeiss Meditec AG
9.8. Leica Microsystems
9.9. PerkinElmer Inc.
9.10. Molecular Devices, LLC
9.11. Danaher Corporation
9.12. Biotech Instruments
CHAPTER 10. GLOBAL LIVE CELL IMAGING MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3.Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
